secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2022-10-20T23:59:59+00:00
Accession:  0001274737-22-000067
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen names John Aballi CEO, succeeding Ron Rocca who resigned
---------------------------------------------------------------

- John Aballi appointed CEO/President and board member effective Oct 16, 2022, replacing Ron Rocca after 11 years.
- Aballi previously SVP/GM Urology and CLIA COO at Veracyte; grew urology unit to $120M+ revenue annually.
- Aballi receives base salary $525,000, target bonus 50% of base, equity award of 350,000 shares/units vesting 4 years.
- Ron Rocca severance: lump sum $424,875, pro-rated incentive compensation, and 9 months COBRA reimbursement.
- Rocca's resignation not due to any disagreement with company's operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/exdx-20221016.htm
  HTML page:      https://secwatch.observer/filing/0001274737-22-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer